Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
13.90
-0.10 (-0.71%)
Nov 7, 2025, 4:00 PM EST - Market closed
Xencor Revenue
Xencor had revenue of $21.00M in the quarter ending September 30, 2025, with 18.00% growth. This brings the company's revenue in the last twelve months to $150.13M, up 38.16% year-over-year. In the year 2024, Xencor had annual revenue of $110.49M, down -36.72%.
Revenue (ttm)
$150.13M
Revenue Growth
+38.16%
P/S Ratio
6.84
Revenue / Employee
$600,528
Employees
250
Market Cap
992.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110.49M | -64.12M | -36.72% |
| Dec 31, 2023 | 174.62M | 10.04M | 6.10% |
| Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
| Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
| Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XNCR News
- 4 days ago - Xencor Reports Third Quarter 2025 Financial Results - Business Wire
- 16 days ago - Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript - Seeking Alpha
- 16 days ago - Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma - Business Wire
- 19 days ago - Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 26 days ago - Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire
- 7 weeks ago - Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release - Seeking Alpha
- 2 months ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 3 months ago - Xencor Reports Second Quarter 2025 Financial Results - Business Wire